NsGene

Ballerup, Denmark Founded: 1999 • Age: 27 yrs
Specializes in drug delivery systems and therapeutics for central nervous system diseases.
Annual revenue - Latest available
Total funding $5.1M 3 rounds
Employees - Tracked headcount
Investors 5 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About NsGene

NsGene is a company based in Ballerup (Denmark) founded in 1999. It operates as a B2B. NsGene has raised $5.14 million across 3 funding rounds from investors including European Union, Neurosearch and Danmarks Eksport- og Investeringsfond. NsGene operates in a competitive market with competitors including Impel NeuroPharma, CraniUS, Cognos Therapeutics, Palyon Medical and Bionxt, among others.

  • Headquarter Ballerup, Denmark
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Nsgene A/S
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $5.14 M (USD)

    in 3 rounds

  • Latest Funding Round
    $303.63 K (USD), Grant

    Feb 01, 2017

  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of NsGene

NsGene has successfully raised a total of $5.14M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $303.63 thousand completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in NsGene

NsGene has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Neurosearch and Danmarks Eksport- og Investeringsfond.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Provision of financing, loans, equity, and insurance for Danish export and investment activities.
Locked Locked Locked
-
Locked Locked Locked
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
Locked Locked Locked
Premium access

Investor details for NsGene

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by NsGene

Investments
Premium access

Investment portfolio details for NsGene

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - NsGene

Premium access

Detailed financials for NsGene

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Nsgene Comparisons

NsGene Primary company
Description
Specializes in drug delivery systems and therapeutics for ce...
Location
Ballerup, Denmark
Founded Year
1999
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for NsGene

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of NsGene

NsGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Impel NeuroPharma, CraniUS, Cognos Therapeutics, Palyon Medical and Bionxt, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Intranasal delivery technology for CNS diseases is developed.
Locked Locked Locked
Drug delivery systems for brain diseases and disorders are developed.
Locked Locked Locked
Cognos Therapeutics is focused on innovative neurological and oncological treatments.
Locked Locked Locked
Develops implantable drug delivery systems for central nervous system disorders.
Locked Locked Locked
Drug formulations and delivery systems for diseases are developed.
Premium access

Detailed competitors of NsGene

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Nsgene

Premium access

Complete news archive for NsGene

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about NsGene

NsGene was founded in 1999 and raised its 1st funding round 6 years after it was founded.

NsGene is headquartered in Ballerup, Denmark.

NsGene is a funded company, having raised a total of $5.14M across 3 funding rounds to date.

NsGene, founded in 1999 in Ballerup, Denmark, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and cns drug delivery. Specializes in drug delivery systems and therapeutics for central nervous system diseases. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.

NsGene's top competitors include Impel NeuroPharma, CraniUS and Cognos Therapeutics.

NsGene has 5 investors. Key investors include European Union, Neurosearch, Danmarks Eksport- og Investeringsfond, DKA Capital, and LD Fonde.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available